Press


NeuroVision Announces Participation in Landmark Alzheimer's A4 Study
arrow

NeuroVision Announces Participation in Landmark Alzheimer's A4 Study

close
 NVI LOGO NEWS RELEASE Media Contact: Sandy VanTel. 808-526-1708Email: sandy@prpacific.comNeuroVision Announces Participation in Landmark Alzheimer’s A4 Study Evaluating Its Novel Retinal Imaging Technology Substudy Will Evaluate NeuroVision’s Novel Retinal Imaging Technology SACRAMENTO, Calif. (June 29, 2016) – NeuroVision Imaging LLC (“NeuroVision”) today announced its participation in a new substudy with investigators at the University of California San Diego School of Medicine (UC San Diego) and the University of Southern California (USC) to be part of the landmark Anti-Amyloid Treatment in Asymptomatic Alzheimer’s (or “A4”) clinical trial.The main A4 study is a public-private partnership, funded by the National Institute on Aging at the National Institutes of Health, Eli Lilly and Company, and several philanthropic organizations. USC’s Alzheimer’s Therapeutic Research Institute coordinates the trial, with about 70 study sites in several countries, including the United States, Canada, Australia and Japan.ildcat is providing support for NeuroVision as it seeks advanced validation and regulatory approval for its retinal imaging technology in connection with the early detection and monitoring of amyloid pathology related to Alzheimer’s disease.The purpose of the A4 study is to test whether a new investigational treatment that may reduce beta-amyloid accumulation in the brain can also slow memory loss caused by Alzheimer’s disease. Amyloid is a protein normally produced in the brain that can build up in older people, forming amyloid plaque deposits.dditionally, Leonard Potter, chief investment officer and president of Wildcat Capital Management, has been named to NeuroVision’s board of directors.Scientists believe this buildup of deposits may play a key role in the eventual development of Alzheimer’s disease-related memory loss. The overall goal of the A4 study is to test whether decreasing amyloid accumulation with an antibody investigational treatment can help slow the memory loss associated with Alzheimer’s disease.“Our best chance of altering the disease may be to start treatment before people have symptoms,” said Dr. Robert Rissman, substudy principal investigator and associate professor of neurosciences at UC San Diego. “Evaluating new approaches such as retinal imaging will allow us to understand how Alzheimer’s neuropathology develops in the eye and how this parallels what is occurring in the brain itself. We are very fortunate to have the opportunity to conduct this substudy in A4 with our USC colleagues.”Using NeuroVision’s retinal imaging technology, the substudy will characterize retinal amyloid imaging findings in subjects with preclinical AD prior to administration of experimental treatment received as part of the primary A4 study protocol. The substudy will also assess longitudinal changes in retinal amyloid imaging in subjects with preclinical AD and whether it correlates with brain amyloid and cognitive change. One hundred subjects will be recruited into the substudy and imaged annually over three years.“If successful, this technique could one day be used in the clinic to identify at-risk patients,” said Dr. Michael Rafii, associate professor of neurology at USC and associate professor of neurosciences at UC San Diego. “Dr. Rissman and I recently identified a strong neuropathological signal using NeuroVision’s retinal imaging system in adults with Down Syndrome, a group of individuals who are at increased risk for developing Alzheimer’s disease.”Steve Verdooner, CEO of NeuroVision, remarked that “this is an exciting opportunity to evaluate our technology in a setting in which it could potentially add significant clinical value. Currently, evaluating amyloid plaque burden in the clinical setting is challenging and has limited scope for scaling up to meet the potential demand for effective new drugs. Our technology is designed to be easy-to-use, reliable and, being noninvasive, have minimal impact on patients. If it works in the way we expect, retinal imaging would streamline enrollment into clinical studies and could help identify candidates for new drugs and monitor their efficacy in a practical and accessible setting.”For more information about the A4 study, please visit A4Study.org.# # #NeuroVision (www.neurovision.com) was formed in 2010 and is headquartered in Sacramento, California. Dr. Keith Black, the company’s chairman and co-founder, is an internationally recognized neurosurgeon, researcher and thought leader in areas of brain and blood-brain barrier function, enhancing the therapeutic effects of treatments in the brain, and optical imaging of the brain. He is the chair of Cedars-Sinai’s Department of Neurosurgery. Steven R. Verdooner, NVI’s CEO as well as a company director, is an experienced medical technology industry veteran who has successfully developed, commercialized and marketed ophthalmological imaging and measurement systems for other diagnostic applications.# # #
NeuroVision Announces $10 Million Series B Financing Led by Wildcat Capital Management with $5 Million
arrow

NeuroVision Announces $10 Million Series B Financing Led by Wildcat Capital Management with $5 Million

close
 NVI LOGO NEWS RELEASE Media Contact: Sandy VanTel. 808-526-1708Email: sandy@prpacific.comNeuroVision Announces $10 Million Series B Financing Led by Wildcat Capital Management with $5 Million Wildcat Capital Management’s Leonard Potter Named to NeuroVision Board SACRAMENTO, Calif. (June 29, 2016) – NeuroVision Imaging LLC has raised a Series B financing round led by a $5 million investment from Wildcat Capital Management, the family office of TPG co-founder David Bonderman. A portion of the Series B financing has been reserved for strategic investors.Wildcat is providing support for NeuroVision as it seeks advanced validation and regulatory approval for its retinal imaging technology in connection with the early detection and monitoring of amyloid pathology related to Alzheimer’s disease.Additionally, Leonard Potter, chief investment officer and president of Wildcat Capital Management, has been named to NeuroVision’s board of directors.“This agreement is an important milestone in the continued development of NeuroVision’s technology,” said Steven Verdooner, NeuroVision CEO. “We are also pleased to welcome Len Potter to our organization. We will benefit greatly from his experience with therapeutic and diagnostic startups as well as his insights and expertise in the world of investment and finance.”“NeuroVision is putting together an impressive scientific track record and garnering the attention of other organizations dedicated to finding answers to the threat of Alzheimer’s disease, which often is likened to a developing tsunami,” Potter said. “I’m happy to become personally involved in the future of the company and I look forward to the advancements that may be possible through our financial support.”A hallmark sign of Alzheimer’s disease is the accumulation of amyloid beta plaque in the brain. Positron emission tomography, or PET scans, and cerebrospinal fluid analysis are currently used to detect amyloid for clinical trials and for the diagnosis of Alzheimer’s disease. These procedures are invasive, inconvenient and costly for clinical trial recruitment, and are impractical for routine screening, disease monitoring and evaluation of therapy response.The retina, the light-sensing structure at the back of the eye, is a developmental outgrowth of the central nervous system and shares many of the brain’s characteristics, enabling the potential of retinal imaging for amyloid detection in Alzheimer’s disease. Previous studies found that amyloid beta plaque that accumulates in the brain also builds up in the retina and shares similar plaque structure and other characteristics. This breakthrough was discovered by a team at Cedars-Sinai Medical Center in Los Angeles led by Keith L. Black, M.D. and Maya Koronyo-Hamaoui, Ph.D. NeuroVision holds the exclusive worldwide license to this technology, which is owned by Cedars-Sinai.# # #About NeuroVision Imaging LLC: NeuroVision (www.neurovision.com) was formed in 2010 and is headquartered in Sacramento, California. The company develops digital imaging and diagnostic solutions for Alzheimer’s disease (AD). In a study published in NeuroImage by members of NVI’s founding team, under the direction of Keith L. Black, M.D. and Maya Koronyo-Hamaoui, Ph.D., noninvasive retinal imaging was validated in transgenic mouse models and human cadaver studies for the early detection of amyloid beta plaque in the retina. NVI is building upon this research and has developed a proprietary test that utilizes a retinal imaging system and a proprietary high-bioavailability curcumin formulation. Commercialization plans include establishment of a simple eye test as a standard of care for noninvasive, high-resolution optical imaging for detection of amyloid beta plaque in AD diagnosis, prognosis assessment and response to therapies. Dr. Black, the company’s chairman and co-founder, is an internationally recognized neurosurgeon, researcher and thought leader in areas of brain and blood-brain barrier function, enhancing the therapeutic effects of treatments in the brain, and optical imaging of the brain. He is the chair of Cedars-Sinai’s Department of Neurosurgery. Steven R. Verdooner, NVI’s CEO as well as a company director, is an experienced medical technology industry veteran who has successfully developed, commercialized and marketed ophthalmological imaging and measurement systems for other diagnostic applications.
NeuroVision Expands Collaboration with Janssen Research & Development LLC to Advance Alzheimer’s Research
arrow

NeuroVision Expands Collaboration with Janssen Research & Development LLC to Advance Alzheimer’s Research

close
 NVI LOGO NEWS RELEASE Media Contact: Sandy VanTel. 808-526-1708Email: sandy@prpacific.comNeuroVision Expands Collaboration with Janssen Research & Development LLC to Advance Alzheimer’s Research SACRAMENTO, Calif. (Feb. 10, 2016) – NeuroVision Imaging LLC has announced completion of a nonexclusive license agreement with Janssen Research & Development LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, that will significantly expand the companies’ collaboration.The collaboration will enable NeuroVision to further validate its retinal imaging technology and develop its technology for potential early detection and monitoring of amyloid pathology related to Alzheimer’s disease. The collaboration is intended to help NeuroVision further develop the foundation for wide, global adoption of its technology, including participation in Janssen clinical trials.The agreement calls for Janssen to provide an initial upfront payment as well as payments for participation in clinical trials and also a milestone payment for regulatory approval.“In terms of emotional toll and financial cost, Alzheimer’s disease is one of the greatest medical challenges of our time. As potential therapies are developed, it is critical that at-risk patients are identified early, before symptoms are seen, at a time when treatments have the potential to make a difference. We believe Janssen’s support and participation will further validate the NeuroVision technology for detection and measurement of beta-amyloid plaque in Alzheimer’s disease, and its progression. We are thrilled to collaborate with Janssen, and look forward to helping empower and enable new treatments,” said Steven Verdooner, CEO of NeuroVision, Sacramento, California.The NeuroVision technology already is being studied in several clinical trials in the U.S. and Australia.Procedures now used to detect amyloid for clinical trials and for the diagnosis of Alzheimer’s disease include positron emission tomography, or PET scans, and cerebrospinal fluid analysis. In addition to being invasive, inconvenient and costly for clinical trial recruitment, these are impractical for routine screening, disease monitoring and evaluation of response to therapy.Retinal imaging for amyloid detection in Alzheimer’s disease is based on the fact that the retina, at the back of the eye, is a developmental outgrowth of the central nervous system and shares many of the brain’s characteristics. Previous studies found that beta-amyloid plaques that accumulate in the brain as a hallmark sign of Alzheimer’s also build up in the retina and share similar plaque structure and other characteristics. This breakthrough was originally discovered by a team at Cedars-Sinai in Los Angeles led by Keith L. Black, M.D., and Maya Koronyo-Hamaoui, Ph.D. NeuroVision holds the exclusive worldwide license to this technology.# # #About NeuroVision Imaging LLC: NeuroVision (www.neurovision.com) was formed in 2010 and is headquartered in Sacramento, California. The company develops digital imaging and diagnostic solutions for Alzheimer’s disease (AD) and eye care markets. In a study published in NeuroImage by members of NVI’s founding team, under the direction of Keith L. Black, M.D., and Maya Koronyo-Hamaoui, Ph.D., noninvasive retinal imaging was validated in transgenic mouse models and human cadaver studies for the early detection of amyloid beta plaque in the retina. NVI is building upon this research and has developed a proprietary test that utilizes a retinal imaging system and also a proprietary high-bioavailability curcumin formulation. Commercialization plans include establishment of a simple eye test as a standard of care for noninvasive high-resolution optical imaging for detection of amyloid beta plaque in AD diagnosis, prognosis assessment and response to therapies. Dr. Black, the Company’s chairman and co-founder, is an internationally recognized neurosurgeon, researcher and thought leader in areas of brain and blood-brain barrier function, enhancing the therapeutic effects of treatments in the brain, and optical imaging of the brain. He is the chair of Cedars-Sinai’s Department of Neurosurgery. Steven R. Verdooner, NVI’s CEO as well as a Company director, is an experienced medtech industry veteran who has successfully developed commercialized and marketed ophthalmological imaging and measurement systems for other diagnostic applications. 
arrow

Wall Street Journal Reports on Neurovision Imaging's Research

Wall Street Journal Reports on Neurovision Imaging's Research
close
From the Wall Street Journal, July 13, 2014COPENHAGEN—Efforts to detect Alzheimer's disease earlier and more cheaply are focusing on signs of the ailment in the eye and sense of smell.Scientists have found that certain biological changes in the retina and lens of the eye, and in the sense of smell, may help predict whether people with no or minor memory issues may go on to develop the progressive brain disease, according to findings presented here Sunday at the Alzheimer's Association International Conference...for the full article, click here.  
arrow

CBS News Report - Eye test may be able to detect Alzheimer's decades before onset

CBS News Report - Eye test may be able to detect Alzheimer's decades before onset
close
NEW YORK - More than 5 million Americans currently have Alzheimer's disease. That number is expected to increase dramatically in the decades ahead. Read the complete article from CBS News here
CNet - Australian scientists developing early detection test for Alzheimer's
arrow

CNet - Australian scientists developing early detection test for Alzheimer's

close
CNet reports on Neurovision Imaging's trial with CSIRO, and interviews Shaun Frost.For the complete article, click here
Dr. Black Presents to Google's Solve for X
arrow

Dr. Black Presents to Google's Solve for X

close
Watch the presentation here.  
arrow

Dr. Black interviewed on KCET

Dr. Black interviewed on KCET
close
Dr. Black  describes the NeuroVisionImaging Alzheimer's test.[youtube width="600" height="365" video_id="VbYBxftK_58?rel=0"] 
arrow

NeuroVision Eye Test Part of Major Alzheimer’s Trial

NeuroVision Eye Test Part of Major Alzheimer’s Trial
close
Researchers are trialing NVI technology for early identification of Alzheimer's Disease. More on the trial can be found here. 
CNN Reports on New Retinal Imaging Test for Alzheimer's
arrow

CNN Reports on New Retinal Imaging Test for Alzheimer's

close
CNN's Dr. Sanjay Gupta takes a look at NeuroVision Imaging's retinal imaging test for Alzheimer's disease. Click here for the full story. 
Dr. Keith Black featured in Discoveries Magazine
arrow

Dr. Keith Black featured in Discoveries Magazine

close

Setting His Sights on Alzheimer’s Disease

Neurosurgeon Keith L. Black, MD, has led pioneering advances in the understanding and surgical treatment of brain cancers and complex neurological conditions. Under his direction, scientists at the Maxine Dunitz Neurosurgical Institute are currently pursuing a breakthrough study of Alzheimer’s disease focused on early detection using a simple eye exam. This work took on greater significance for Dr. Black when his mother, Lillian, was diagnosed with Alzheimer’s several years ago. Read more here:http://www.discoveriesmagazine.org/qa-with-keith-l-black-md/
arrow

NeuroVision Imaging Eye Test Shows Potential for Early Detection of Changes Associated with Alzheimer’s Disease in Clinical Study

NeuroVision Imaging Eye Test Shows Potential for Early Detection of Changes Associated with Alzheimer’s Disease in Clinical Study
close
“If longitudinal studies demonstrate that our test can detect changes in retinal plaque over a short period of time, we see great potential for using the technology not just for early detection, but also for measuring response to therapy,” said NeuroVision CEO Steven Verdooner.